265 related articles for article (PubMed ID: 7484057)
1. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
3. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
[TBL] [Abstract][Full Text] [Related]
4. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
[TBL] [Abstract][Full Text] [Related]
5. Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid.
Eldrup E; Møller SE; Andreasen J; Christensen NJ
Clin Sci (Lond); 1997 Apr; 92(4):423-30. PubMed ID: 9176043
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
Goldstein DS; Holmes C; Lopez GJ; Wu T; Sharabi Y
Parkinsonism Relat Disord; 2018 May; 50():108-112. PubMed ID: 29475591
[TBL] [Abstract][Full Text] [Related]
7. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
8. Catecholamines in CSF, plasma, and tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson's disease.
Tyce GM; Ahlskog JE; Carmichael SW; Chritton SL; Stoddard SL; van Heerden JA; Yaksh TL; Kelly PJ
J Lab Clin Med; 1989 Aug; 114(2):185-92. PubMed ID: 2754305
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
Tohgi H; Abe T; Takahashi S; Nozaki Y; Kikuchi T
Neurosci Lett; 1991 Jun; 127(2):212-4. PubMed ID: 1908962
[TBL] [Abstract][Full Text] [Related]
10. Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies.
Ahlskog JE; Kelly PJ; van Heerden JA; Stoddard SL; Tyce GM; Windebank AJ; Bailey PA; Bell GN; Blexrud MD; Carmichael SW
Mayo Clin Proc; 1990 Mar; 65(3):305-28. PubMed ID: 2314121
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatographic assay for CSF catecholamines using electrochemical detection.
Seppala T; Scheinin M; Capone A; Linnoila M
Acta Pharmacol Toxicol (Copenh); 1984 Aug; 55(2):81-7. PubMed ID: 6496117
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
Eldrup E; Clausen N; Scherling B; Schmiegelow K
Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
[TBL] [Abstract][Full Text] [Related]
13. DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting.
Eldrup E; Richter EA
Am J Physiol Endocrinol Metab; 2000 Oct; 279(4):E815-22. PubMed ID: 11001763
[TBL] [Abstract][Full Text] [Related]
14. New approaches to evaluate sympathoadrenal system activity in experiments on earth and in space.
Kvetnansky R; Noskov VB; Blazicek P; Macho L; Grigoriev AI; Goldstein DS; Kopin IJ
Acta Astronaut; 1994 Oct; 34():243-54. PubMed ID: 11540743
[TBL] [Abstract][Full Text] [Related]
15. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Tohgi H; Abe T; Takahashi S
J Neural Transm Park Dis Dement Sect; 1993; 5(1):27-34. PubMed ID: 8439390
[TBL] [Abstract][Full Text] [Related]
16. Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
Baraczka K; Fekete MI; Kanyicska B
J Neural Transm; 1983; 58(3-4):299-304. PubMed ID: 6420516
[TBL] [Abstract][Full Text] [Related]
17. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
Chia LG; Cheng FC; Kuo JS
J Neurol Sci; 1993 Jun; 116(2):125-34. PubMed ID: 8336158
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease.
Kim AR; Ugryumov MV
Dokl Biochem Biophys; 2015; 464():308-11. PubMed ID: 26518555
[TBL] [Abstract][Full Text] [Related]
19. Rapid procedure for chromatographic isolation of DOPA, DOPAC, epinephrine, norepinephrine and dopamine from a single urinary sample at endogenous levels.
Dalmaz Y; Peyrin L
J Chromatogr; 1978 Jan; 145(1):11-27. PubMed ID: 621235
[TBL] [Abstract][Full Text] [Related]
20. Perioperative concentrations of catecholamines in the cerebrospinal fluid and plasma during spinal anesthesia.
Oehmke MJ; Podranski T; Mann M; Frickey N; Kuhn DF; Hempelmann G
Acta Anaesthesiol Scand; 2008 Apr; 52(4):487-92. PubMed ID: 18339154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
